NuCanaNCNA
About: NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
Employees: 28
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
13% more funds holding
Funds holding: 15 [Q2] → 17 (+2) [Q3]
0.21% less ownership
Funds ownership: 0.66% [Q2] → 0.46% (-0.21%) [Q3]
32% less capital invested
Capital invested by funds: $871K [Q2] → $590K (-$281K) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Oppenheimer Leland Gershell 58% 1-year accuracy 35 / 60 met price target | 1,578%upside $25 | Outperform Maintained | 3 Sept 2024 |
Oppenheimer Leland Gershell 58% 1-year accuracy 35 / 60 met price target | 9,967%upside $150 | Outperform Reiterated | 19 Aug 2024 |
